China Adds Domestic AI Chips to Government Procurement List as U.S. Considers Easing Nvidia Export Curbs 
GameStop Misses Q3 Revenue Estimates as Digital Shift Pressures Growth 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
Gulf Sovereign Funds Unite in Paramount–Skydance Bid for Warner Bros Discovery 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
SoftBank Shares Slide as Oracle’s AI Spending Plans Fuel Market Jitters 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
ANZ Faces Legal Battle as Former CEO Shayne Elliott Sues Over A$13.5 Million Bonus Dispute 
Microsoft Unveils Massive Global AI Investments, Prioritizing India’s Rapidly Growing Digital Market 
JD.com Pledges 22 Billion Yuan Housing Support for Couriers as China’s Instant Retail Competition Heats Up 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
Air Transat Reaches Tentative Agreement With Pilots, Avoids Strike and Restores Normal Operations 
SK Hynix Considers U.S. ADR Listing to Boost Shareholder Value Amid Rising AI Chip Demand 
Westpac Director Peter Nash Avoids Major Investor Backlash Amid ASX Scrutiny 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Pittsburgh, Nov. 08, 2017 -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced that President & CEO Kenneth I. Moch will present at the Stifel 2017 Healthcare Conference at 8:45 a.m. on November 15, 2017 at the Lotte New York Palace Hotel.
Mr. Moch’s presentation will include a corporate update as well as summary of results from the company’s Phase 1b/2a study of CT1812 in patients with mild-to-moderate Alzheimer’s disease. These results, which were recently presented at the annual Clinical Trials on Alzheimer’s Disease (CTAD) conference, showed that CT1812 was well tolerated and generated a differential change compared to placebo in the levels of several key cerebrospinal fluid proteins that are dysregulated in Alzheimer’s disease.
About CT1812
Cognition’s lead product candidate, CT1812, has completed a Phase 1b/2a clinical study (COG0102) in patients with mild-to-moderate Alzheimer’s disease and has been granted Fast Track designation by the US FDA. This highly brain penetrant compound targets the sigma-2 receptor complex on neuronal synapses, displacing toxic beta amyloid (Aβ) oligomers from their binding sites on brain cells and clearing them into the cerebrospinal fluid. CT1812 has been shown in multiple Alzheimer’s disease models to stop memory loss. Study COG0102 was supported in part under Award Number RF1AG054176 from The National Institute on Aging of the National Institutes of Health.
About Cognition Therapeutics, Inc.
Cognition Therapeutics is a privately held biopharmaceutical company developing a pipeline of disease modifying small molecule drug candidates to treat neurocognitive disorders. Cognition’s lead candidate, CT1812, is a proprietary first-in-class, orally available small molecule in development for the treatment of mild-to-moderate Alzheimer’s disease. CT1812 and Cognition’s other pipeline candidates were identified using the company’s disease-relevant screening and novel chemistry platforms. Additional information about Cognition and its product candidates may be found online at http://www.cogrx.com.
Forward-Looking Statements
This press release contains “forward-looking statements” concerning the development and commercialization of Cognition’s products, the potential benefits and attributes of such products, and Cognition’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Cognition undertakes no obligation to update any forward-looking statements for any reason.
Cognition Therapeutics [email protected] 412-465-0095 Aline Sherwood Scienta Communications [email protected] 312-238-8957
